Drugs / Caffeine
Caffeine
also known as
Caffeine Citrate · cafeine · anhydrous caffeine · CAF · Cafcit · cafeislaine c · Caffeine alkaloid · Caffeine Anhydrous · +47 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Peyona (previously Nymusa) | — | 2009-07-02 | europa.eu ↗ |
| Label expansion | US (FDA) | CAFCIT | — | 2000-04-12 | fda.gov ↗ |
| Approved | US (FDA) | CAFERGOT | — | 1948-11-26 | fda.gov ↗ |
Trials 247 · started per year
today
US approved 1948
EU approved 2009
1
1
1
1
1
2
4
3
9
4
6
7
11
9
10
8
10
10
15
13
10
13
10
15
14
10
15
12
8
13
194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials | ||||||
| Phase 0 | NCT07466732 | Dec 2025 → Mar 2026 overdue | — | Liverpool John Moores University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06693960 | Sep 2024 → Dec 2026 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT06359197 | Apr → Aug 2024 | — | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 0 | NCT05478863 | Jan 2023 → Oct 2024 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT04730193 | Feb 2021 → Aug 2022 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT03937687 | May 2019 → Nov 2020 | — | University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT03577730 | Jul 2018 → Nov 2019 | neuropathy, painful | University of Michigan | Completed | No outcome recorded |
| Phase 0 | NCT01747590 | Jul 2011 → Dec 2013 | drug-induced mental disorder | Mclean Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT01435837 | Oct 2010 → May 2013 | voice disorders | Southern Illinois University Carbondale | Completed | No outcome recorded |
| Phase 0 | NCT02135965 | Apr 2009 → Aug 2011 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
| Phase 0 | NCT00432887 | Jul 2004 → Feb 2007 | type 2 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 1108 trials | ||||||
| Phase 1 | NCT07710768 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07665723 | Jun 2026 → Jul 2027 expected | ulcerative colitis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT07570121 | Jun 2026 → Jun 2027 expected | apnea of prematurity, bronchopulmonary dysplasia, respiratory distress syndrome in premature infants | Indiana University | Recruiting | No outcome recorded |
| Phase 1 | NCT07426042 | Apr → May 2026 overdue | — | Min Kyu Park | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06973005 | May → Jul 2025 | liver disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06917508 | Mar → Jun 2025 | respiratory syncytial virus infectious disease | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06821698 | Feb → May 2025 | — | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06686628 | Nov 2024 → Nov 2025 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT06632990 | Nov 2024 → Apr 2025 overdue | — | Allyx Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06564441 | Oct 2024 → Dec 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06905496 | Jun 2024 → Dec 2025 overdue | apnea of prematurity | Nishtar Medical University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05906303 | Dec 2023 → Dec 2024 | — | The Reading Hospital and Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT05932277 | Jun → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05852769 | May → Aug 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05830799 | Mar → May 2023 | — | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 1 | NCT05657613 | Jan → Jun 2023 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT05685407 | Jan → Apr 2023 | sexual disorder | University of Texas at Austin | Completed | No outcome recorded |
| Phase 1 | NCT05594615 | Oct → Nov 2022 | COVID-19 | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05532358 | Sep 2022 → Jan 2023 | — | MODAG GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05445232 | Jul 2022 → Feb 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05334108 | Apr → Aug 2022 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04246762 | Nov 2021 → Jun 2022 | rheumatoid arthritis | R-Pharm International, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05067439 | Oct 2021 → Feb 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04814498 | May → Sep 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04764851 | Feb → Apr 2021 | — | Emalex Biosciences Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06215430 | Jan → Apr 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04525235 | Jan → Aug 2021 | tuberculosis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04679948 | Dec 2020 → Mar 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04655040 | Dec 2020 → Mar 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05121714 | Dec 2020 → May 2021 | — | Abivax S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04425902 | Dec 2020 → Mar 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04643249 | Nov → Dec 2020 | mitochondrial disease | Abliva AB | Completed | No outcome recorded |
| Phase 1 | NCT04201197 | Nov 2020 → Mar 2022 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04315961 | Sep 2020 → Feb 2023 | — | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1 | NCT04504045 | Sep 2020 → May 2022 | type 2 diabetes mellitus | University of Southern Denmark | Terminated | No outcome recorded |
| Phase 1 | NCT04254783 | May 2020 → Oct 2022 | Crohn disease, ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT04275115 | Feb → Apr 2020 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04233437 | Feb → May 2020 | stroke disorder | Moleac Pte Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03970798 | May → Jul 2019 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04144712 | Apr 2019 → Oct 2020 | apnea of prematurity | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT03948243 | Apr 2019 → Jul 2020 | — | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 1 | NCT03718884 | Oct 2018 → Oct 2019 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03720366 | Oct 2018 → Sep 2023 | acute myeloid leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03556592 | Aug 2018 → Mar 2020 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03505853 | Apr → Nov 2018 | acute intermittent porphyria | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02098785 | Mar → Sep 2018 | liver disorder | University of Birmingham | Withdrawn | No outcome recorded |
| Phase 1 | NCT03432793 | Feb → Apr 2018 | — | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT03358706 | Feb 2018 → Nov 2021 | Crohn disease, ulcerative colitis | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT03864042 | Jan 2018 → Jul 2022 | cancer, metastatic melanoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03333824 | Dec 2017 → Jan 2019 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03195946 | Jun 2017 → Jan 2018 | hypersensitivity reaction disease | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT03131973 | May → Nov 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03187496 | May → Jun 2017 | metabolic dysfunction-associated steatohepatitis | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03058419 | Mar → May 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02993471 | Dec 2016 → Nov 2017 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02772601 | Sep 2016 → Jun 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02655614 | May 2016 → Mar 2020 | amyotrophic lateral sclerosis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02740712 | Apr 2016 → Mar 2017 | neoplasm | pharmaand GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02688088 | Mar 2016 → Feb 2018 | metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02685462 | Jan → Feb 2016 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02520752 | Dec 2015 → Jan 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02647086 | Dec 2015 → Jul 2016 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02578277 | Nov → Dec 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02629354 | Nov 2015 → Jan 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02623296 | Oct 2015 → Feb 2016 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02567682 | Sep 2015 → May 2016 | sickle cell disease | Global Blood Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02397382 | Jun 2015 → Aug 2016 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02434861 | May → Jul 2015 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02361619 | Feb 2015 → Sep 2016 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02391688 | Nov 2014 → Apr 2015 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT02254148 | Oct → Dec 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02211079 | Sep → Nov 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02115763 | Apr 2014 → May 2015 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 1 | NCT02045966 | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02128321 | Jan → Feb 2014 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02225093 | Oct 2013 → Feb 2014 | prostate cancer | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02056743 | Sep → Oct 2013 | — | Chonbuk National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01934569 | Sep → Nov 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01879371 | Jun → Jul 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01731067 | Nov 2012 → May 2013 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT01636557 | Oct 2012 → Oct 2013 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01596647 | May 2012 → Jul 2014 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01525628 | Apr 2012 → Dec 2013 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01517399 | Dec 2011 → Aug 2013 | cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01443039 | Sep 2011 → Feb 2014 | obesity disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT01834547 | May 2011 → Apr 2013 | — | K. Lieb | Completed | No outcome recorded |
| Phase 1 | NCT01386593 | May 2011 → Jan 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01275170 | Jan 2011 → Mar 2012 | infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01289561 | Jan 2011 → Jan 2015 | alcohol-induced mental disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01188525 | Aug 2010 → Jul 2011 | — | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1 | NCT01845194 | Dec 2009 → Oct 2013 | mitochondrial membrane transport disorder | Institute of Application-oriented Research and Clinical Trials GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01001299 | Nov 2009 → Feb 2012 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00964106 | Aug 2009 → Aug 2011 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01476176 | Jul → Aug 2009 | headache disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00930306 | Jun → Sep 2009 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00824057 | Jan → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00726726 | Aug → Oct 2008 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00741468 | Jul → Sep 2008 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00790114 | Jul → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02182336 | Jun → Sep 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00513110 | Aug 2007 → Aug 2008 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00443170 | Nov 2006 → ? | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00401583 | Jul 2006 → Feb 2008 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02243553 | Jan → Jul 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256813 | Sep → Dec 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00302289 | Jan → Dec 2000 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT07469852 | Jan → Mar 2026 overdue | — | Liverpool John Moores University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06538584 | Sep 2024 → Jul 2026 overdue | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04044001 | Nov 2019 → Mar 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 1/2 | NCT02832336 | Oct 2016 → May 2017 | narcolepsy | King Saud University | Completed | No outcome recorded |
| Phase 1/2 | NCT01086722 | Feb 2010 → Feb 2013 | morbid obesity | Hospital del Mar Medical Research Institute (IMIM) | Completed | No outcome recorded |
| Phase 1/2 | NCT00733993 | Apr 2008 → Jul 2011 | cocaine dependence | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT00515294 | Oct 2006 → Oct 2009 | alcohol-related disorders, neurodevelopmental disorder, sleep disorder | Boston University | Completed | No outcome recorded |
| Phase 1/2 | NCT00299416 | Feb 2003 → Jan 2009 | ischemic stroke | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT06972108 | Sep 2026 → Aug 2027 expected | meconium aspiration syndrome | University of Alberta | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07216365 | Jun 2026 → Sep 2027 expected | infantile apnea | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07262060 | May 2026 → Mar 2030 expected | acute kidney injury | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT07456670 | Apr 2026 → Mar 2028 expected | — | Queen's University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06345716 | Apr 2024 → Mar 2025 overdue | urinary tract obstruction | University of Monastir | Recruiting | No outcome recorded |
| Phase 2 | NCT05574400 | Feb 2023 → Apr 2026 | cognitive impairment with or without cerebellar ataxia, delirium | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT05232734 | Nov 2022 → Dec 2025 | — | Singapore General Hospital | Suspended | No outcome recorded |
| Phase 2 | NCT04562116 | Dec 2021 → Jun 2023 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT05079880 | Aug → Oct 2021 | gallbladder disorder | Tunis University | Unknown | No outcome recorded |
| Phase 2 | NCT04972123 | Jul 2021 → Aug 2023 | syncope, familial vasovagal | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT03768492 | Jun 2020 → Dec 2027 expected | breast carcinoma | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04132336 | Nov 2019 → Mar 2020 | neuropathy, painful | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03321734 | Jan 2019 → Jun 2023 | — | Children's National Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02311088 | Dec 2014 → Dec 2015 | — | Uppsala University | Terminated | No outcome recorded |
| Phase 2 | NCT01950520 | Feb 2014 → Dec 2022 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT01190735 | Aug 2010 → Feb 2011 | Parkinson disease | Ron Postuma | Completed | No outcome recorded |
| Phase 2 | NCT00879775 | Apr → Jul 2009 | cancer | Korea Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT01080677 | Jan 2007 → Sep 2009 | migraine disorder | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00377975 | Jan 2003 → Nov 2004 | obesity disorder | Pennington Biomedical Research Center | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT06026163 | Oct 2023 → Oct 2027 expected | pulmonary immaturity | Ministry of Health, Saudi Arabia | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03556917 | Jun 2018 → Mar 2019 | cellulitis | Universidade Norte do Paraná | Completed | No outcome recorded |
| Phase 2/3 | NCT01755702 | Jul 2009 → Mar 2010 | headache disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2/3 | NCT00459420 | Apr 2007 → Jul 2011 | Parkinson disease, hypersomnia | Ron Postuma | Completed | No outcome recorded |
| Phase 2/3 | NCT00495092 | Jan 2005 → Dec 2009 | cocaine dependence | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00302263 | Jan → Apr 2005 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 2/3 | NCT00302276 | Jan → Jul 2004 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT06855108 | Apr 2026 → Dec 2029 expected | brain hypoxia - ischemia | NICHD Global Network for Women's and Children's Health | Recruiting | No outcome recorded |
| Phase 3 | NCT05485805 | Sep 2022 → Jan 2024 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT04570085 | Mar 2021 → Dec 2027 expected | Alzheimer disease | University Hospital, Lille | Recruiting | No outcome recorded |
| Phase 3 | NCT02985671 | Jan → Sep 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02582996 | Apr 2020 → Apr 2021 | migraine disorder | Ache Laboratorios Farmaceuticos S.A. | Suspended | No outcome recorded |
| Phase 3 | NCT03508167 | Jan → Oct 2020 | — | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04001712 | Apr → May 2019 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT03340727 | Feb 2019 → Jan 2023 | apnea of prematurity | NICHD Neonatal Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT02863575 | Oct 2017 → Apr 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03003000 | Dec 2016 → Sep 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02735070 | Sep 2016 → Mar 2017 | — | Brainfarma | Unknown | No outcome recorded |
| Phase 3 | NCT01999829 | Oct 2013 → Jun 2016 | atrial fibrillation | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01929031 | Aug 2013 → Mar 2014 | neuropathy, painful, tooth disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01842633 | Apr 2013 → Mar 2015 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT01426971 | Dec 2012 → Jun 2013 | — | Sanofi | Withdrawn | No outcome recorded |
| Phase 3 | NCT01421433 | May → Aug 2012 | — | Farmoquimica S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01172405 | Oct 2010 → Oct 2012 | headache disorder | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01875159 | Jul 2010 → Dec 2011 | — | American SIDS Institute | Completed | No outcome recorded |
| Phase 3 | NCT00826280 | Mar 2009 → Jul 2010 | coronary artery disorder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00573170 | Feb 2008 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00564824 | Nov 2007 → Sep 2009 | coronary artery disorder | Sheba Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00471952 | Apr 2007 → Feb 2008 | migraine with aura, migraine without aura | Diamond Headache Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00182312 | Oct 1999 → Mar 2007 | apnea of prematurity | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT02183688 | Sep 1998 → Jan 2003 | migraine disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01408069 | — | — | EMS | Withdrawn | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT06518603 | Jun 2026 → May 2027 expected | apnea of prematurity, respiratory distress syndrome in premature infants | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 4 | NCT07466628 | Nov 2024 → Jul 2025 | — | Liverpool John Moores University | Completed | No outcome recorded |
| Phase 4 | NCT06763172 | May 2023 → Dec 2026 expected | — | Hsiao-Ying Wey | Recruiting | No outcome recorded |
| Phase 4 | NCT07022496 | Apr 2023 → Jul 2025 overdue | migraine disorder | Ain Shams University | Recruiting | No outcome recorded |
| Phase 4 | NCT05454332 | Apr 2022 → Dec 2025 overdue | lung disorder | Hospital de Clinicas de Porto Alegre | Recruiting | No outcome recorded |
| Phase 4 | NCT04868565 | May 2021 → Oct 2023 | apnea of prematurity | Children's Hospital of Chongqing Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03951649 | Feb 2020 → Dec 2022 | headache disorder, pregnancy disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03360903 | Jan → Dec 2018 | — | University of Chicago | Completed | No outcome recorded |
| Phase 4 | NCT03086473 | Feb 2017 → Jan 2022 | apnea of prematurity, bronchopulmonary dysplasia | Jennifer Shepherd | Unknown | No outcome recorded |
| Phase 4 | NCT02760615 | Nov 2016 → Aug 2020 | Crohn disease, ulcerative colitis | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT02974114 | Oct 2016 → Feb 2017 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 4 | NCT02291666 | Apr 2015 → Jul 2019 | type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT02372110 | Mar → Nov 2015 | anxiety | University of Texas at Austin | Completed | No outcome recorded |
| Phase 4 | NCT01766050 | Jan → Apr 2013 | transplant rejection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01693809 | Jan → Oct 2012 | — | Hospital do Servidor Publico Estadual | Unknown | No outcome recorded |
| Phase 4 | NCT01466348 | Feb → Apr 2011 | common cold | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01248468 | Nov 2010 → Mar 2011 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00495183 | Jan 2009 → Jul 2010 | cocaine dependence | Hospital Universitari Vall d'Hebron Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT00809055 | Nov 2008 → Dec 2010 | apnea of prematurity, brain injury, intracerebral hemorrhage | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01048515 | Feb → Nov 2005 | — | Herning Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00117520 | Jul 2002 → Mar 2006 | — | Herning Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00131690 | Apr 1996 → Aug 2002 | — | The Danish Epdiemiology Science Centre | Completed | No outcome recorded |
| Phase not applicable47 trials | ||||||
| — | NCT07536568 | Apr → Jul 2026 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT07402902 | Mar → Jul 2026 overdue | disorder of fatty acid and ketone body metabolism | Universidad Rey Juan Carlos | Enrolling by invitation | No outcome recorded |
| — | NCT06461429 | Nov 2025 → Dec 2050 expected | — | University of Melbourne | Not yet recruiting | No outcome recorded |
| — | NCT07305935 | Oct 2025 → Mar 2026 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT07652424 | Jan → May 2025 | circadian rhythm sleep disorder | The Higher Institute of Sport and Physical Education of Sfax | Completed | No outcome recorded |
| — | NCT06704711 | Nov → Dec 2024 overdue | — | University of Gaziantep | Not yet recruiting | No outcome recorded |
| — | NCT06145490 | Oct 2024 → May 2025 | panic disorder | Uppsala University | Completed | No outcome recorded |
| — | NCT06210984 | Jan 2024 → Dec 2025 | — | St. Mary's University, Twickenham | Unknown | No outcome recorded |
| — | NCT05761756 | Nov 2023 → Aug 2026 overdue | epilepsy | Duke University | Recruiting | No outcome recorded |
| — | NCT06636825 | Nov 2023 → Sep 2024 | respiratory underresponsiveness to hypoxia and hypercapnia | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| — | NCT05741385 | Oct 2023 → Aug 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT05790161 | Mar 2023 → Sep 2024 | — | Psychiatric Hospital of the University of Basel | Unknown | No outcome recorded |
| — | NCT06693505 | Oct 2022 → Aug 2024 | CGF1, sleep disorder | China Medical University Hospital | Completed | No outcome recorded |
| — | NCT05521386 | Sep 2022 → Mar 2023 | — | St Mary's University College | Unknown | No outcome recorded |
| — | NCT05261594 | Mar 2022 → Mar 2023 | panic disorder | Uppsala University | Completed | No outcome recorded |
| — | NCT04202406 | Jan → May 2021 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT04044976 | Aug 2019 → Jun 2021 | respiratory distress syndrome in premature infants | University of Florence | Completed | No outcome recorded |
| — | NCT03720665 | Oct 2018 → Nov 2019 | — | University Medical Center Goettingen | Completed | No outcome recorded |
| — | NCT03337945 | Apr 2018 → Jun 2021 | cirrhosis of liver | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT04869176 | Nov 2017 → Jul 2018 | infantile apnea | University of Ljubljana | Completed | No outcome recorded |
| — | NCT03298347 | Oct 2017 → Oct 2018 | apnea of prematurity | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Unknown | No outcome recorded |
| — | NCT03400111 | Sep 2017 → Mar 2019 | malposition of teeth with or without hypodontia/oligodontia | Damascus University | Completed | No outcome recorded |
| — | NCT05409339 | May 2016 → Oct 2017 | circadian rhythm sleep disorder, substance withdrawal syndrome | Psychiatric Hospital of the University of Basel | Completed | No outcome recorded |
| — | NCT02740660 | Apr 2016 → Oct 2017 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
| — | NCT02789527 | Nov 2015 → Apr 2017 | — | Estella S. Poloni | Completed | No outcome recorded |
| — | NCT02510911 | Aug 2015 → Aug 2020 | colorectal neoplasm, diverticulitis of colon, paralytic ileus | Thomas Steffen | Terminated | No outcome recorded |
| — | NCT02461693 | Jun → Oct 2015 | CGF1 | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT02917889 | Feb 2015 → Aug 2016 | autonomic nervous system disorder | São Paulo State University | Unknown | No outcome recorded |
| — | NCT02438072 | Dec 2014 → Dec 2015 | depressive disorder | University Hospital, Geneva | Unknown | No outcome recorded |
| — | NCT02411318 | Sep 2014 → Dec 2019 | defective phagocytic cell chemotaxis | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT02071615 | Aug 2013 → Mar 2014 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT01815203 | Mar → Jul 2013 | eating disorder, obesity disorder | Uppsala University | Completed | No outcome recorded |
| — | NCT01751724 | Dec 2012 → Jan 2016 | apnea of prematurity, respiratory failure | University of Miami | Terminated | No outcome recorded |
| — | NCT01361217 | Sep 2011 → Jun 2012 | — | University of Washington | Completed | No outcome recorded |
| — | NCT02119416 | Aug 2011 → Oct 2012 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| — | NCT01349205 | Mar 2010 → Jun 2014 | disorder of pharynx, obstructive sleep apnea syndrome | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| — | NCT01477294 | Jan → Mar 2010 | — | Technical University of Lisbon | Completed | No outcome recorded |
| — | NCT00809627 | Jan 2007 → May 2008 | — | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
| — | NCT00268554 | Dec 2005 → Jul 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00253929 | Nov 2005 → Feb 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00487227 | Jun → Nov 2005 | — | Northumbria University | Completed | No outcome recorded |
| — | NCT00184847 | Mar 2005 → ? | ischemic disease | Radboud University Medical Center | Suspended | No outcome recorded |
| — | NCT00245375 | Jan → Dec 2005 | gallbladder disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| — | NCT00961792 | Mar 2004 → Sep 2026 expected | alcohol dependence | University of Chicago | Active not recruiting | No outcome recorded |
| — | NCT00184912 | Sep 2003 → Jan 2006 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00310323 | Jan 2003 → Feb 2006 | obstructive sleep apnea syndrome | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01710722 | Feb 2001 → Feb 2002 | obesity disorder | Pennington Biomedical Research Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 75 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06097767 Comparator | Oct 2023 → Apr 2024 | — | Al-Azhar University | Unknown | No outcome recorded |
| Phase 0 | NCT07204379 Comparator | Jan → Jul 2023 | — | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT06448780 Comparator | Jul 2024 → Jul 2026 overdue | brain hypoxia - ischemia | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05295784 Comparator | May 2024 | acute kidney injury, brain hypoxia - ischemia | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 1 | NCT04942340 Comparator | May 2023 → Apr 2026 | — | University of Chicago | Withdrawn | No outcome recorded |
| Phase 1 | NCT05713773 Comparator | Oct → Dec 2019 | metabolic syndrome X, obesity disorder | Aphaia Pharma US LLC | Completed | No outcome recorded |
| Phase 1 | NCT03913221 Comparator | Aug 2019 → Jan 2023 | brain hypoxia - ischemia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT02125643 Comparator | Aug 2014 → May 2015 | — | University of Oklahoma | Terminated | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01944215 Comparator | Sep 2013 → Apr 2015 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01570569 Comparator | Jan → Mar 2011 | — | Inje University | Completed | No outcome recorded |
| Phase 1 | NCT01187862 Background | Jul 2010 → Feb 2011 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00692510 Background | Nov 2007 → Sep 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00437632 Background | Mar 2007 → Aug 2008 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02323698 Comparator | Jan 2019 → Mar 2021 | spinal cord injury | Spaulding Rehabilitation Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02594358 Comparator | Oct 2014 → Dec 2017 | amblyopia | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06327152 Comparator | Feb 2024 → Dec 2026 expected | apnea of prematurity | University of California, Irvine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02408328 Comparator | Jun → Dec 2020 | apnea of prematurity | Boston Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT03097900 Comparator | Nov 2017 → Dec 2019 | ileus | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 2 | NCT02344225 Comparator | Jan 2015 → Jun 2018 | retinopathy of prematurity | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00273754 Comparator | Sep 2003 → May 2008 | obstructive sleep apnea syndrome | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00134381 Comparator | May 2003 → Nov 2012 | — | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05170464 Comparator | Jan → Mar 2022 | episodic memory defect leukoencephalopathy, substance withdrawal syndrome | Western University, Canada | Completed | No outcome recorded |
| Phase 2/3 | NCT03022838 Comparator | Feb 2017 → Jul 2019 | migraine disorder, substance withdrawal syndrome | Nordland Hospital | Terminated | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07626437 Comparator | May 2026 → Jun 2027 expected | nasal cavity disorder, viral respiratory tract infection | Brainfarma | Recruiting | No outcome recorded |
| Phase 3 | NCT05229965 Comparator | Nov 2022 → Jun 2023 | — | University of Monastir | Completed | No outcome recorded |
| Phase 3 | NCT05682807 Comparator | Jun 2022 → Jun 2024 | bronchopulmonary dysplasia | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT04872270 Comparator | Apr 2021 → Apr 2022 | arthropathy | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT02706015 Background | Oct 2020 → May 2021 | migraine disorder | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02862977 Comparator | Nov 2017 → Jun 2019 | musculoskeletal system disorder | EMS | Completed | No outcome recorded |
| Phase 3 | NCT01738178 Comparator | Apr 2014 → May 2016 | Parkinson disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 3 | NCT01686646 Comparator | Nov 2011 → Nov 2012 | common cold | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01462370 Background | Nov 2011 → Jun 2012 | primary dysmenorrhea | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02103777 Comparator | Sep 2011 → Sep 2013 | apnea of prematurity | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01020357 Comparator | Nov 2009 → Jul 2013 | apnea of prematurity | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT00388128 Comparator | Sep 2006 → May 2009 | intermittent vascular claudication | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT02048215 Comparator | Feb 2000 → Jan 2001 | obesity disorder | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 416 trials | ||||||
| Phase 4 | NCT06401083 Comparator | Dec 2023 → Dec 2027 expected | apnea of prematurity, respiratory failure | Semmelweis University | Recruiting | No outcome recorded |
| Phase 4 | NCT04259333 Comparator | Mar → Dec 2020 | neuropathy, painful, substance-related disorder | Blake Raggio | Unknown | No outcome recorded |
| Phase 4 | NCT04950660 Comparator | Dec 2019 → Jan 2024 | adolescent idiopathic scoliosis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 4 | NCT03910088 Comparator | Apr → Jun 2019 | intracranial hypotension | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03694886 Comparator | Oct 2018 → Mar 2019 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT03400423 Comparator | Feb 2018 → Jun 2019 | — | Western University, Canada | Completed | No outcome recorded |
| Phase 4 | NCT02567968 Comparator | Aug 2016 → May 2017 | — | University of Chicago | Completed | No outcome recorded |
| Phase 4 | NCT05919732 Background | Mar 2016 → Mar 2018 | — | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01783561 Comparator | Oct 2013 → May 2014 | — | Sharp HealthCare | Completed | No outcome recorded |
| Phase 4 | NCT01610401 Comparator | May 2012 → Jan 2013 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01402089 Background | Jan 2012 → Jul 2015 | gastrointestinal stromal tumor, non-small cell lung carcinoma, renal cell carcinoma | Markus Joerger | Completed | No outcome recorded |
| Phase 4 | NCT01629329 Comparator | Nov 2010 → Apr 2014 | migraine disorder | Albert Einstein Healthcare Network | Terminated | No outcome recorded |
| Phase 4 | NCT00851175 Comparator | Mar → Aug 2009 | atherosclerosis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00781586 Comparator | Oct 2007 → Apr 2008 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00430170 Comparator | Jan → Mar 2007 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00164112 Background | Nov 2004 → Jun 2005 | — | Bassett Healthcare | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT07655245 Comparator | Jun → Sep 2026 expected | hypotensive disorder | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT06978777 Comparator | Jan → May 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| — | NCT06972849 Comparator | Oct 2025 → Dec 2029 expected | apnea of prematurity | University of Melbourne | Not yet recruiting | No outcome recorded |
| — | NCT07076654 Comparator | Jul → Oct 2025 | hypotensive disorder | Cairo University | Completed | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT04662125 Comparator | Dec 2020 → Aug 2023 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT04280263 Comparator | Feb 2020 → Jun 2021 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT02832401 Comparator | Sep 2016 → Aug 2018 | schizophrenia | Nova Scotia Health Authority | Completed | No outcome recorded |
| — | NCT02524249 Comparator | Sep 2015 → Jun 2019 | apnea of prematurity, bronchopulmonary dysplasia | Wayne State University | Terminated | No outcome recorded |
| — | NCT02515526 Comparator | Jun → Aug 2015 | — | University of Cologne | Completed | No outcome recorded |
| — | NCT02677584 Comparator | Mar 2015 → Nov 2018 | apnea of prematurity | Mansoura University Children Hospital | Completed | No outcome recorded |
| — | NCT02214290 Comparator | Sep 2012 → Mar 2014 | hypertensive disorder | Florida State University | Completed | No outcome recorded |
| — | NCT01596907 Comparator | May 2012 → Jul 2015 | morbid obesity | Oregon Weight Loss Surgery, LLC | Completed | No outcome recorded |
| — | NCT01501747 Comparator | Feb 2012 → Feb 2013 | — | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT01435486 Comparator | Nov 2011 → May 2014 | bronchiolitis, infantile apnea | Hamad Medical Corporation | Completed | No outcome recorded |
| — | NCT01350089 Comparator | Jan 2011 → May 2012 | alcohol-induced mental disorder | Medical University of Vienna | Unknown | No outcome recorded |
| — | NCT02095405 Comparator | Feb 2010 → Aug 2012 | atrial fibrillation | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| — | NCT00981929 Comparator | Sep → Dec 2009 | — | University of Southern Denmark | Terminated | No outcome recorded |
| — | NCT00426010 Comparator | Jan 2007 → Feb 2009 | — | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00130026 Comparator | Mar → Oct 2005 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT00205166 Comparator | Jun 1999 → Dec 2004 | coronary artery disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00162383 Background | Jul 1995 → Dec 2020 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
Evidence & citations 59 cited values
Every value below carries the sentence it was read from. 323 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caffeine | “We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 2023308“Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 “two pieces of caffeinated chewing gum at an absolute dose of 200 mg (Military Energy Gum®, Ford Gum and Machine Go, Akron, NY, USA) (CAF trial) or two pieces of similar looking...” NCT06693505 ↗ “A CYP probe cocktail composed of approved, commercially available drugs (caffeine, flurbiprofen, omeprazole, and midazolam) will be administered concomitantly as a single-dose...” NCT07426042 ↗ “The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior...” NCT00245375 ↗ “The BTZ-043 groups also received oral dolutegravir (a third of participants) or a probe drug cocktail (caffeine [probe for CYP1A2], tolbutamide [CYP2C9], dextromethorphan...” PMID 39793592 ↗ Jan 2025 “The objective of the present study was to investigate the acute and sub-chronic effect of a supplement containing green tea extract, capsaisin, caffeine, tyrosine and calcium...” NCT00302276 ↗ “A single dose of selective substrates (probe drugs) was administered orally on days 15 and 30: caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan...” PMID 37768317 ↗ Sep 2023 “CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low...” NCT03508167 ↗ “Caffeine, a methyl xanthine compound widely known for its central nervous system (CNS) stimulant properties, has shown potential to accelerate emergence from general anesthesia.” NCT07536568 ↗ “And the caffeine presents mechanisms that are not totally clear, but it may relieves the pain by activating of the central noradenosine pathway (pain suppressing system).” NCT02706015 ↗ “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 “Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.” NCT02688088 ↗ “Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)” NCT06930872 ↗ “Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)” NCT05657613 ↗ “Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).” NCT06693960 ↗ “Caffeine was added in the same proportion as found in a commercially available caffeinated beer (69 mg/12 oz of beer at 4.8% alc. by vol).” PMID 21134017 ↗ Dec 2010 “The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine.” NCT02735070 ↗ “probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).” NCT00401583 ↗ “Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.” NCT01421433 ↗ “Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution” NCT02623296 ↗ “The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine.” PMID 32851583 ↗ Nov 2020 “Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)” NCT04201197 ↗ “Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without calcium together with 5 mg propranolol.” NCT00302263 ↗ “The drug was administered orally in a single opaque capsule containing 200 mg caffeine/placebo daily in the morning for 1 week.” PMID 32215834 ↗ Mar 2020 “Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg” NCT04233437 ↗ “Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure” NCT00134381 ↗ “Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally” NCT03718884 ↗ “During the caffeine maintenance condition, participants will ingest 200 mg of caffeine orally in capsules three times daily.” NCT04315961 ↗ “Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20” NCT01001299 ↗ “modified "karolinska cocktail" (dextromethorphan, caffeine, losartan, omeprazole and paracetamol) before bariatric surgery” NCT01086722 ↗ “codeine 30mg-acetaminophen 300mg-caffeine 15 mg tabelt by mouth every 4 hours for 7 days postoperatively prn pain” NCT04259333 ↗ “butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg)” NCT00573170 ↗ “oral dose of the Cooperstown Cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan)” NCT02434861 ↗ “Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)” NCT04275115 ↗ “Anhydrous caffeine (5 mg/kg body mass) was administered orally in an opaque capsule at 18:00.” NCT07652424 ↗ “1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg” NCT01408069 ↗ “The purpose of this study is to determine whether caffeine has any effect on birth weight.” NCT00131690 ↗ “Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)” NCT03951649 ↗ “Caffeine (2 mg/kg orally, rounded to nearest 50 mg) with collection of a 12-hour urine.” NCT00164112 ↗ “GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam” NCT02567682 ↗ “Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion” NCT02033707 ↗ “Caffeine + Warfarin (plus vitamin K) + Omeprazole + Dextromethorphan + Midazolam” NCT02993471 ↗ “includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan” NCT03505853 ↗ “In the case of caffeine , the dosage corresponds to two cups of coffee.” NCT02071615 ↗ “caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole” NCT03720366 ↗ “Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine)” NCT03400111 ↗ “CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19” PMID 39707077 ↗ Dec 2024 “Oral administration of Caffeine will boost ANS activity” NCT02372110 ↗ “dextromethorphan, caffeine, omeprazole, and midazolam” NCT05334108 ↗ “200 mg of ibuprofen and 40 mg of caffeine anhydrous” NCT07204379 ↗ “Caffeinol is a combination of caffeine and alcohol.” NCT00299416 ↗ “the mouth rinse form of caffeine (400 mg)” NCT06704711 ↗ “Caffeine tablets for oral use, 200 mg/day” NCT03195946 ↗ “experimental paracetamol with caffeine” NCT01476176 ↗ “Caffeine capsule 250 mg, oral intake” NCT06145490 ↗ “Caffeine capsule 150 mg, oral intake” NCT05261594 ↗ “65mgcaffeine+500mg paracetamol” NCT06345716 ↗ “Caffeine 200 mg Midazolam 2 mg” NCT05532358 ↗ “* caffeine: 200 mg oral tablet” NCT04764851 ↗ “Caffeine (a cup of coffee)” NCT01731067 ↗ “Caffeine (50 mg, N06BC01)” NCT02438072 ↗ “100 mg caffeine (CYP1A2)” PMID 31099895 ↗ Jul 2019 “Caffeine, Koffein Meda” NCT05830799 ↗ “CYP1A2 Caffeine 50 mg” NCT04814498 ↗ “Caffeine (200 mg)” NCT00741468 ↗ “Drug: Caffeine” NCT01636557 ↗ “Caffeine 200mg” NCT02056743 ↗ “Drug: Caffeine” NCT06973005 ↗ |
| Known as | anhydrous caffeine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01462370 ↗ |
| Known as | CAF | “caffeine (CAF)” NCT06704711 ↗ |
| Known as | Cafcit | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | cafeine | “Group 3: Paracetamol-cafeine group who will receive an association of 500 mg of Paracetamol and 65 mg of cafeine : one pill 3 times a day for 7 days .” NCT05229965 ↗1“CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE” NCT01443039 ↗ |
| Known as | cafeislaine c | “we will use cafeislaine c (caffeine) +galvanic current” NCT03556917 ↗ |
| Known as | Caffeine alkaloid | “Drug: Caffeine alkaloid” NCT01190735 ↗ |
| Known as | Caffeine Anhydrous | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03694886 ↗ |
| Known as | caffeine base | “active drug (caffeine base)” NCT03321734 ↗ |
| Known as | Caffeine Citrate | “It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml...” NCT06097767 ↗11“Caffeine citrate is a combination of caffeine and citric acid, commonly used as a central nervous system stimulant. It is primarily used to treat apnea of prematurity in neonates.” NCT06905496 ↗ “Neonates will receive caffeine citrate (IV or enteral) in 20 mg/kg loading dose within 24 hours of life, followed by a 5 mg/kg/day maintenance dose.” NCT07305935 ↗ “Drug: Caffeine Citrate” NCT03340727 ↗ “Drug: Caffeine Citrate” NCT07216365 ↗ |
| Known as | Caffeine component of anoquan | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of cafergot | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of darvon compound | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of dhc plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of esgic | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of excedrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of femcet | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of fioricet | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of fiorinal | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of invagesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of invagesic forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of lanorinal | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of medigesic plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of migergot | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of norgesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of orphengesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of orphengesic forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of synalgos-dc | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of synalgos-dc-a | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of trezix | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of triad | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine component of wigraine | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine melting point standard | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine mixture with citric acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine tablet (CVS Pharmacy) | “Caffeine tablet (CVS Pharmacy)” NCT02214290 ↗ |
| Known as | Caffeine, citrated | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Caffeine, Koffein Meda | “Caffeine, Koffein Meda” NCT05830799 ↗ |
| Known as | caffeinospire | “It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml...” NCT06097767 ↗ |
| Known as | Caffeinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Citrated caffeine | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Coffeinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Durvitan | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | FEMA NO. 2224 | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Gencebok | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Guaranine | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Guinama Anhydrous Powder | “Caffeine (Guinama Anhydrous Powder)” NCT07402902 ↗ |
| Known as | Nodoz | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | NSC-5036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Percoffedrinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04679948 ↗ |
| Known as | Peyona | “Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)” NCT02098785 ↗ |
| Known as | Peyona (previously nymusa) | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Pro-plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Synalgos | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Vivarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Yeast-vite | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Known as | Zanthine | ChEMBL registry synonym — accepted as the source's own label CHEMBL113 ↗ |
| Action | Inhibit | “Methylxanthines block a naturally occurring substance, called adenosine” NCT00182312 ↗ |
| Modality | Small molecule | “Standard treatment of care for apnea of prematurity is the administration of methylxanthines, specifically caffeine citrate, as a respiratory stimulant.” NCT00809055 ↗ |
| Route | Intravenous | “administered as a single IV dose approximately 15 minutes before emergence from anesthesia” NCT00130026 ↗ |